Home

Tina Susan Nova

CIK 1302605 · Executive Chairperson · last filed 2026-06-08

Tina Susan Nova is an Executive Chairperson who has filed 82 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for AUPH, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$10.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.8M across reported positions. 24 SEC filings were submitted jointly with ARENA PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.77M

Companies

9

Total Filings

82

Lifetime Open-Market Net

-$10.18M

Filer Profile

Reported Address
C/O ARENA PHARMACEUTICALS, INC.
6166 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
Formerly Known As
Nova Bennett Tina (2008–2008)
Related Filers
ARENA PHARMACEUTICALS INC — 24 joint filings, latest 2022-03-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AUPH Director — $16.08 — $0 2 2026-06-08
AZTA Director 15,772 $31.33 $494.1K $0 4 2026-02-06
XGN Executive Chairperson — $7.58 — $0 7 2025-06-12
ARENA PHARMACEUTICALS INC (ARNA) Delisted Director 0 $99.99 $0 -$1.23M 18 2022-03-11
VCYT President, CLIA U.S. 76,988 $42.53 $3.27M $0 8 2022-03-07
OPGEN INC (OPGNW) Delisted Director 750 — — $0 4 2019-09-03
GENOPTIX INC (GXDX) Delisted President and CEO 25 — — -$8.95M 29 2011-03-07
CYPRESS BIOSCIENCE INC (CYPB) Delisted Director — — — $0 1 2010-01-06
CYPRESS BIOSCIENCE INC (NSTR) Delisted Director — — — $0 4 2009-01-07

Recent Filings

82 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-08 AUPH Grant (A) — $0 EDGAR
2026-02-06 AZTA Grant (A) +5,663 $157.7K EDGAR
2025-06-12 XGN Grant (A) — $0 EDGAR
2025-05-16 AUPH Grant (A) — $0 EDGAR
2025-02-11 AZTA Grant (A) +4,040 $211.4K EDGAR
2024-06-12 XGN Grant (A) — $0 EDGAR
2024-02-13 AZTA Grant (A) −2,465 -$162.5K EDGAR
2023-06-20 XGN Grant (A) — $0 EDGAR
2023-02-15 AZTA Grant (A) +3,604 $0 EDGAR
2022-06-21 XGN Grant (A) — $0 EDGAR
Showing 1–10 of 82
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.